Navigation Links
Research: Chemoresponse assay helps boost ovarian cancer survival
Date:4/25/2013

This spring, a team of researchers has released results from an eight-year study that shows improved survival rates for women diagnosed with ovarian cancer who undergo cancer tumor testing to determine the best treatment.

Part of the team was Richard G. Moore, MD, director of the Center for Biomarkers and Emerging Technologies and a gynecologic oncologist with the Program in Women's Oncology at Women & Infants Hospital of Rhode Island.

"Essentially, we have demonstrated that by using a tissue sample from the patient's tumor and a chemoresponse assay, we are able to determine which treatment may or may not work for her," Dr. Moore explains of the study, which was presented at a recent meeting of the Society of Gynecologic Oncology and in the trade publication Cure.

"This study shows that a woman with recurrent ovarian cancer could benefit from having a biopsy and chemosensitivity testing. The results from such testing will allow for the identification of chemotherapeutics that are active against the patient's disease and those that are not resulting in decreased toxicity from ineffective treatments. Learning that personal directed therapies may improve overall survival for these patients made this the first study in two decades to show a significant increase in survival in recurrent ovarian cancer."

The study, launched in 2004, included 283 women. Of those, 262 had successful biopsies which were tested in vitro, or in a test tube. The assay ChemoFx, by Precision Therapeutics, tested up to 15 approved treatment regimens on the samples, identifying chemotherapy drugs and regimens to which each tumor might be sensitive. The study was non-interventional, meaning that physicians chose the treatment regimens without knowing of the assay results. The researchers then evaluated the assay's result against actual patient outcomes.

"The assay identified at least one treatment to which the tumor would be sensitive in 52% of patients in the study," Dr. Moore says. "Overall, median survival was 37.5 months for patients with treatment-sensitive tumors, compared to 23.9 months for intermediate and resistant tumors."

Assay-directed therapy has long been debated among oncologists, he continues. Such debate provided the impetus for this study.


'/>"/>

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Women & Infants Hospital
Source:Eurekalert

Related medicine news :

1. Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved
2. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
3. Research: NCAA football exploits players in invisible labor market
4. Kinsey research: Postpartum women less stressed by threats unrelated to the baby
5. Research: Lupus drugs carry no significant cancer risk for patients
6. Research: Military women may have higher risk for STIs
7. Gut microbiota research: Pinpointing a moving target
8. Research: Brain cant cope with making a left-hand turn and talking on hands-free cell phone
9. UTHealth research: Low incidence of venous insufficiency in MS
10. Multiple sclerosis research: The thalamus moves into the spotlight
11. Research: Women over 40 still need effective contraception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, ... in KLAS category winner, has named Daniel P. Bullington as chief technology officer. ... technology platform and product offerings,” says Justin Neece, president. “Daniel is an excellent ...
(Date:5/23/2017)... Beach, CA (PRWEB) , ... May 23, 2017 , ... ... Partners was honored to serve earlier this month as a Guest Speaker and Contributor ... the British Royal Family and Common Purpose. , Walter Schindler and ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and ... Sonoma County. While officials call for diligence, asking homeowners to scout for any open ... health concerns. Along with the annoying buzz of mosquitos is the buzz associated with ...
(Date:5/23/2017)... New York, New York (PRWEB) , ... May ... ... partnership with NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, ... Embryology Training Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech ...
(Date:5/23/2017)... ... ... New patients from Charleston, SC, are now welcome to receive a full mouth ... or without a referral. A full mouth reconstruction can transform the appearance of the ... SC. Those who suffer from gum disease, misaligned teeth or jaw pain can also ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... is demonstrating its wireless, handheld ultrasound scanners this ... Gynecologists Annual Scientific Meeting (ACOG) in ... 2017. "Clarius is the perfect ... fetal growth and heart rate, and evaluate pregnancy-related ...
Breaking Medicine Technology: